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Nav1.7, a peripheral neuron voltage-gated sodium
channel, is essential for pain and olfaction in mice
and humans. We examined the role of Nav1.7 as
well as Nav1.3, Nav1.8, andNav1.9 in differentmouse
models of chronic pain. Constriction-injury-depen-
dent neuropathic pain is abolished when Nav1.7 is
deleted in sensory neurons, unlike nerve-transec-
tion-related pain, which requires the deletion of
Nav1.7 in sensory and sympathetic neurons for
pain relief. Sympathetic sprouting that develops
in parallel with nerve-transection pain depends on
the presence of Nav1.7 in sympathetic neurons.
Mechanical and cold allodynia required distinct
sets of neurons and different repertoires of sodium
channels depending on the nerve injury model.
Surprisingly, pain induced by the chemotherapeutic
agent oxaliplatin and cancer-induced bone pain do
not require the presence of Nav1.7 sodium channels
or Nav1.8-positive nociceptors. Thus, similar pain
phenotypes arise through distinct cellular and mo-
lecular mechanisms. Therefore, rational analgesic
drug therapy requires patient stratification in terms
of mechanisms and not just phenotype.INTRODUCTION
Pain afflicts a fifth of the population; there is an urgent need for
new analgesic drugs with minimal side effects. There is strong
evidence that, in most chronic pain conditions arising from nerve
damage or inflammation, peripheral nerve block can cause pain
relief in humans, proving that peripheral drive is critical to chronic
pain (Aguirre et al., 2012). However, our understanding of the
functional diversity of peripheral sensory neurons is limited,
although attempts have been made to link histochemical
markers to function with limited success. The developmental
complexity of sensory neuron specification has been extensivelyCanalyzed (Lallemend and Ernfors, 2012), but the links to function
remain obscure. Here, we explore the role of voltage-gated so-
dium channels in different pain syndromes and provide evidence
for a diversity of mechanisms in peripheral pain pathways that
may help to explain recent failures to develop new analgesic
drugs targeting peripheral neurons.
Studies of human monogenic disorders of pain perception
have drawn attention to the voltage-gated sodium channels
in sensory neurons (Eijkelkamp et al., 2012; Waxman, 2013),
particularly Nav1.7 as a potential drug target, because loss of
function in this channel leads to chronic insensitivity to pain
(CIP) (Cox et al., 2006, Goldberg et al., 2007). Modeling this
loss-of-function syndrome in mice recapitulates the human
pain-free phenotype; acute thermal and mechanical insults
have no behavioral consequences, whereas inflammatory pain
is also abolished in inbred mouse strains lacking Nav1.7 in
peripheral neurons (Minett et al., 2012; Nassar et al., 2004).
Although the analgesia associated with loss of Nav1.7 function
is dramatic, modality-specific pain therapies are more desirable
for most chronic pain conditions where general analgesia could
lead to inadvertent self-harm.
Earlier studies suggested that seemingly similar neuropathic
pain models differed mechanistically (Kim et al., 1997). Neuro-
pathic pain can be either sympathetically maintained or sympa-
thetically independent (Roberts, 1986). Here, we examined a
number of models including the spinal nerve transection (SNT)
model (Kim and Chung, 1992) and the chronic constriction injury
(CCI) model (Bennett and Xie, 1988). In the SNT model, mechan-
ical and cold allodynia are associated with the invasion of the
dorsal root ganglion (DRG) by postganglionic adrenergic sympa-
thetic axons (Ramer and Bisby, 1998a, 1998c). In contrast, CCI is
thought to trigger an immune response leading to a ‘‘neuritis’’
(Campbell and Meyer, 2006), where surgical lumbar sympathec-
tomy produces no signification change in mechanical or cold
allodynia (Kim et al., 1997). A furthermodel associatedwith nerve
damage, the oxaliplatin model of chemotherapeutic-induced
neuropathic pain, was investigated (Renn et al., 2011) because
painful neuropathies affect a third of all patients who undergo
chemotherapy (Velasco and Bruna, 2010). Additionally, we
examined spontaneous and movement-evoked pain behavior
associated with cancer-induced bone pain in a syngeneic modelell Reports 6, 301–312, January 30, 2014 ª2014 The Authors 301
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Figure 1. Comparison of Transgenic Mice Reveals Tissue-Specific Roles for Nav1.7 in Mechanical and Cold Allodynia after CCI Surgery as
Well as a Role Specifically in Sympathetic Neurons after SNT Surgery
Behavioral responses of different Nav1.7 tissue-specific knockouts to the von Frey and acetone test following CCI (A) and L5 SNT surgery (B). Nav1.7Nav1.8 (blue
squares, n = 9) do not develop CCI-induced cold allodynia (Aa) but do develop mechanical allodynia (Ab) in comparison to littermate mice (white squares, n = 8).
Nav1.7Advill (red squares, n = 8) do not develop CCI-induced cold (Ac) or mechanical allodynia (Ad) in comparison to littermate mice (white squares, n = 9).
Nav1.7Wnt1 (green squares, n = 9) do not develop CCI-induced cold (Ae) nor mechanical allodynia (Af) in comparison to littermate mice (white squares, n = 6).
Nav1.7Nav1.8 (blue squares, n = 6) develop both SNT-induced cold (Ba) and mechanical allodynia (Bb) in comparison to littermate mice (white squares, n = 6).
Nav1.7Advill (red squares, n = 6) develop both SNT-induced cold (Bc) and mechanical allodynia (Bd) in comparison to littermate mice (white squares, n = 9).
Nav1.7Wnt1 (green squares, n = 9) do not develop SNT-induced cold allodynia (Be) in comparison to littermate mice (white squares, n = 12). Data analyzed by two-
way analysis of variance followed by the Bonferroni post hoc test. Results are presented as mean ± SEM. **p < 0.01 and ***p < 0.001 (individual points). See also
Figure S1.of metastatic bone cancer. Bone metastasis is a common
complication for patients suffering from advanced lung, breast,
prostate, or skin cancers and is the most common source of
severe cancer pain (Kinnane, 2007; Mercadante, 1997).
Here, we have used models of neuropathic and cancer-
induced bone pain to investigate the role of Nav1.7, as well as
other voltage-gated sodium channels in the development of
pain syndromes. We crossed floxed (Scn9a) Nav1.7 mice with
different tissue-restricted Cre mouse strains to generate noci-
ceptor-specific (Nav1.7Nav1.8), pan-DRG (Nav1.7Advill), and pan-
DRG and sympathetic (Nav1.7Wnt1) Nav1.7 knockout mouse
strains and examined the effects on pain behavior. We also
compared the effects of deleting Nav1.7 in utero or in adult ani-
mals to examine any developmental effects that may contribute
to CIP. Surprisingly, we found that classical nociceptors defined
by the presence of the sodium channel Nav1.8, or the sodium
channel Nav1.7 that have been linked to all forms of acute and
inflammatory pain (Minett et al., 2012; Nassar et al., 2004) are
not required for ongoing pain in models of cancer-induced
bone pain or oxaliplatin-induced neuropathic pain. We also
found that phenotypically identical pain syndromes are induced
through different molecular mechanisms in distinct sets of
sensory and sympathetic neurons. This functional redundancy
raises questions about the organization of peripheral pain path-
ways and strategies for treating pain.302 Cell Reports 6, 301–312, January 30, 2014 ª2014 The AuthorsRESULTS
Generation of Nav1.7 Conditional Knockout Mouse
Strains
We used the Cre-loxP system to generate a number of
conditional Nav1.7 knockout mouse strains. Floxed (Scn9a)
Nav1.7 mice were crossed with strains where Cre expression
is driven by either the Nav1.8 promoter (Nav1.7Nav1.8), expressed
in >90% of neurons expressing markers of nociceptors (Nassar
et al., 2004; Shields et al., 2012), the Advillin promoter
(Nav1.7Advill), expressed in all DRG neurons (Minett et al.,
2012), and the Wnt1 promoter (Nav1.7Wnt1), expressed in tissue
derived from the neural tube, including sensory and sympathetic
neurons (Danielian et al., 1998).
Pain-Modality-Specific Neurons and Nav1.7 in
Neuropathic Pain Models
The three different tissue-specific Nav1.7 transgenic knockout
mouse strains were examined after CCI of the sciatic nerve, or
SNT of the fifth lumbar segment. Both surgical models produce
robust cold and mechanical allodynia. In DRG neurons, Nav1.7
mediates the increased sensitivity to both the acetone and
the von Frey test following CCI surgery (Figure 1A). A comparison
of the Nav1.7Nav1.8 and Nav1.7Advill behavioral responses
reveals a modality-specific role for Nav1.7 within different DRG
subpopulations. Nav1.7Nav1.8 mice do not develop acetone-
induced cold allodynia (Figure 1Aa) but show normal mechanical
allodynia (Figure 1Ab). This is also true for the partial nerve liga-
tion (Seltzer et al., 1990) surgically induced neuropathic pain
model (Figures S1A and S1B). In contrast, deleting Nav1.7
from all DRG neurons attenuates both cold and mechanical
allodynia (Figures 1Ac–1Af). Figure 1B demonstrates that
Nav1.7 expression within DRG neurons is not critical for cold
or mechanical allodynia in the sympathetically mediated SNT
model. Both Nav1.7Nav1.8 and Nav1.7Advill mice develop both
cold and mechanical allodynia normally following SNT surgery
(Figures 1Ba–1Bd), demonstrating that pain associated with
the SNT model does not directly arise from Nav1.7-positive
nociceptors, unlike the CCI model. In contrast, Nav1.7Wnt1
mice develop neither cold (Figure 1Be) nor mechanical allodynia
(Minett et al., 2012) demonstrating that Nav1.7 expressed within
peripheral sympathetic neurons is essential for the SNT-induced
mechanical and cold allodynia.
Interactions between sympathetic neurons and the neuronal
somata of DRG neurons have been described since the era of
Ramo´n y Cajal in the 19th century (Garcı´a-Poblete et al., 2003).
Nerve injury has been shown to induce increased sympathetic
sprouting into the DRG (McLachlan et al., 1993; Ramer and
Bisby, 1998c). A high innervation density of sympathetic axons
(highlighted by yellow arrow heads) was found within ipsilateral
L4 DRG 30 days following SNT surgery (Figure 2A), in compari-
son to contralateral L4 DRG (Figure 2B). These sprouting sympa-
thetic axons form ‘‘baskets’’ around the DRG cell body of large
myelinated DRG neurons (McLachlan et al., 1993; Ramer and
Bisby, 1998a), an example of which can be seen in Figure 2C.
Quantification of sympathetic sprouting following SNT surgery
shows that Nav1.7Nav1.8 and Nav1.7Advill mice are indistinguish-
able from littermate controls (Figure 2D). In contrast, Nav1.7Wnt1
mice show the same low level sympathetic sprouting density in
the ipsilateral as the contralateral L4 DRG following SNT surgery.
No significant change in DRG size was observed in the three
Nav1.7 knockout mouse strains or littermate controls. Nav1.7
expression within sympathetic neurons is therefore required for
sympathetic sprouting following nerve injury. Inhibition of
Nav1.7-mediated sympathetic sprouting is associated with a
loss of cold (Figure 1Be) and mechanical allodynia in Nav1.7Wnt1
mice (Minett et al., 2012).
Global deletion of other voltage-gated sodium channels, such
as Nav1.3, Nav1.8, or Nav1.9 does not reduce the sympathetic
sprouting density following nerve damage (Figure 2E). Perform-
ing a chemical sympathectomy on Nav1.7Advill mice prior to SNT
surgery (Figure 2F) recapitulates the Nav1.7Wnt1 behavioral
phenotype (Minett et al., 2012). It has previously been reported
that approximately 10% of lumbar DRG neurons are tyrosine
hydroxylase (TH) positive, although they are thought to be
dopaminergic because they lack the enzymes required for
norepinephrine or epinephrine production (Brumovsky et al.,
2006). Microarray analysis of DRG from mice where the
Nav1.8-positive DRG population has been ablated (Nav1.8DTA)
shows a significant decrease in TH (10-fold) in comparison
to littermates, indicating an overlap between the Nav1.8 and
TH-positive neurons (Abrahamsen et al., 2008). However,
the disruption of the Nav1.8-positive DRG population in theCNav1.7Nav1.8 mice does not alter the development of pain
following SNT. Together this suggests that TH-positive DRG
subpopulation is not critical for the development SNT-induced
cold and mechanical allodynia.
The combination of chemical sympathectomy and the loss of
Nav1.7 from all DRG neurons shows greater attenuation of
SNT-induced mechanical allodynia than chemical sympathec-
tomy alone (Figure 2F), suggesting the nociceptors contribute
to SNT-evoked mechanical allodynia. Cutaneous injection of
the sympathetic transmitter norepinephrine rekindles the sponta-
neous pain and dynamic mechanical hyperalgesia in posttrau-
matic neuralgia patients,whichhadbeen relievedby sympathetic
block (Torebjo¨rk et al., 1995). Peripheral sensory neurons
have been shown to develop noradrenergic sensitivity following
nerve lesion through an upregulation of a2-adrenoceptors
in intact afferent fibers (Baron et al., 1999). Interestingly, intra-
plantar injection of norepinephrine induces mechanical allo-
dynia in Nav1.7Wnt1 mice 14 days after SNT surgery (Figure 2G).
This means that peripheral pain pathways can be activated
in the absence of Nav1.7 after nerve damage. Norepinephrine-
induced SNT mechanical allodynia can be detected within
10 min and is still apparent 5 days postinjection. Importantly,
intraplantar injection of norepinephrine does not induce
mechanical allodynia in naive mice (Figure S2). Norepinephrine-
mediated coupling between sympathetic and DRG neurons is
thus critical for the development of pain in the sympathetically
mediated SNT neuropathic pain model. Sympathetic sprouting
following SNT is mainly associated with large diameter sensory
neurons (Xie et al., 2011), as is the vast majority of norepineph-
rine-evoked spontaneous neuronal activity following SNT (Liu
et al., 1999).
Distinct Modality-Specific Roles for Nav1.3, Nav1.8, and
Nav1.9 in Neuropathic Pain
A comparison of the behavioral responses of Nav1.3, Nav1.8,
and Nav1.9 global knockout mouse strains in the CCI (Figure 3A)
and SNT (Figure 3B) neuropathic pain models reveals modality-
specific roles for these sodium channels. Deletion of Nav1.3
reduces cold allodynia (Figure 3Aa) as well as the magnitude
of mechanical allodynia (Figure 3Ab) following CCI surgery.
However, mice lacking Nav1.8 show an attenuated response
to acetone-induced cold allodynia (Figure 3Ac) but develop
mechanical allodynia normally (Figure 3Ad). The same is also
true for Nav1.9 knockout mice (Figures 3Ae and 3Af). Interest-
ingly, Figure 3B shows that all these behavioral phenotypes are
restricted to the CCI models of neuropathic pain. Both cold
and mechanical allodynia develop normally in mice lacking
Nav1.3 (Figures 3Ba and 3Bb), Nav1.8 (Figures 3Bc and 3Bd),
and Nav1.9 (Figures 3Be and 3Bf) following SNT surgery. Addi-
tionally, sympathetic sprouting into the DRG develops normally
in the Nav1.3, 1.8, and 1.9 global knockout mouse strains
(Figure 2E), demonstrating that only Nav1.7 is required for sym-
pathetic sprouting following SNT surgery.
Oxaliplatin-Induced Pain andCancer-InducedBonePain
Are Nav1.7 Independent
Both Nav1.7Advill (Figures S3A and S3B) and Nav1.7Wnt1 (Figures
4A and 4B)mice developmechanical and cold allodynia normallyell Reports 6, 301–312, January 30, 2014 ª2014 The Authors 303
Figure 2. Spinal Nerve Transection Fails to Trigger Sympathetic Sprouting in Nav1.7Wnt1 Mice, which Can Be Sensitized by Norepinephrine
(A) Yellow arrows show examples of sympathetic sprouting (tyrosine hydroxylase, red) into the ipsilateral DRG following SNT surgery (scale bar = 100 mm).
(B) An example of a contralateral DRG showing no sympathetic sprouting (tyrosine hydroxylase, red) following SNT surgery (scale bar = 200 mm).
(C) An example of a sympathetic ‘‘basket’’ (tyrosine hydroxylase, red) formed around a large diameter (N52, green) DRG neuron (scale bar = 20 mm).
(D) Quantitation of sympathetic sprouting into the ipsilateral and contralateral L4 DRG following SNT. Littermates (white columns, n = 3), Nav1.7Nav1.8 (blue
columns, n = 3), Nav1.7Advill (red columns, n = 3), and Nav1.7Wnt1 (green columns, n = 3).
(E) Quantitation of sympathetic sprouting into the L4 DRG following SNT. Littermates (white columns, n = 3), Nav1.3KO (orange columns, n = 3), Nav1.8KO (light
blue columns, n = 3), and Nav1.9KO (turquoise columns, n = 3).
(legend continued on next page)
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Figure 3. Behavioral Responses of Nav1.3, Nav1.8, and Nav1.9 Knockout Mice Reveal Critical Roles in Modality-Specific Responses to
CCI-Induced Pain but Not Sympathetically Mediated SNT Pain
Behavioral von Frey and acetone responses of Nav1.3, Nav1.8, or Nav1.9 knockouts following CCI (A) and L5 SNT surgery (B). Nav1.3KO mice (orange squares,
n = 6) show reduced CCI-induced cold allodynia (Aa) andmechanical allodynia (Ab) in comparison to littermate mice (white squares, n = 10). Nav1.8KOmice (light
blue squares, n = 8) show diminished CCI-induced cold allodynia (Ac) but do develop mechanical allodynia (Ad) in comparison to littermate mice (white squares,
n = 10). Nav1.9KO mice (turquoise squares, n = 8) show diminished CCI-induced cold allodynia (Ae) but do develop mechanical allodynia (Af) in comparison to
littermate mice (white lines, n = 8). Nav1.3KOmice (orange squares, n = 10) develop both L5 SNT-induced cold (Ba) and mechanical allodynia (Bb) in comparison
to littermatemice (white squares, n = 8). Nav1.8KOmice (light blue squares, n = 8) develop L5 SNT-induced cold (Bc) andmechanical allodynia (Bd) in comparison
to littermate mice (white squares, n = 8). Nav1.9KO mice (turquoise squares, n = 10) develop L5 SNT-induced cold (Be) and mechanical allodynia (Bf) in com-
parison to littermatemice (white squares, n = 7). Data analyzed by two-way analysis of variance followed by the Bonferroni post hoc test. Results are presented as
mean ± SEM. **p < 0.01 and ***p < 0.001 (individual points).following oxaliplatin treatment when compared to littermate con-
trols. This shows that the expression of Nav1.7, within either
DRG or sympathetic neurons is not required for this pain syn-
drome. Similarly, global deletion of Nav1.3, Nav1.8, or Nav1.9
does not attenuate either mechanical or cold allodynia in this
model (Figures S3C–S3H) despite the suggestion that enhanced
Nav1.8 expression could contribute to oxaliplatin-induced cold
pain (Descoeur et al., 2011). Finally, bothmechanical and cold al-
lodynia develop normally in Nav1.8DTA mice (Figures 4C and 4D).
The oxaliplatin model thus has a distinct underlying mechanism
from both sympathetically dependent and independent surgi-
cally induced neuropathic pain models, as well as inflammatory
pain (Minett et al., 2012; Nassar et al., 2004) and does not require
the presence of Nav1.8-positive nociceptors.
In a mouse model of metastatic cancer pain induced by intra-
femoral injection of syngeneic LL/2 lung carcinoma cells, we
found that, as with oxaliplatin-evoked pain, deleting Nav1.7(F) Behavioral von Frey responses following SNT surgery on 6-OHDA sympathec
mice, in comparison to unsympathectomized littermate controls (white squares,
(G) Intraplantar norepinephrine (200 ng) injection sensitizes Nav1.7Wnt1 mice (blac
alone in Nav1.7Wnt1 mice 14 days after SNT surgery (green line and squares, n = 6).
hoc test. Results are presented as mean ± SEM. **p < 0.01 and ***p < 0.001 (ind
See also Figure S2.
Cexpression in the peripheral nervous system did not result in
the loss of pain behavior. No behavioral deficits were observed
in either limb use or weight-bearing ratio (Figures 4E and 4F),
although deleting Nav1.7 from the peripheral nervous system
produces striking behavioral deficits in all acute, inflammatory,
and surgically induced neuropathic pain models tested (Minett
et al., 2012; Nassar et al., 2004). Ablation of Nav1.8-positive
neurons in the Nav1.8DTA mouse strain leads to the loss of
many pain modalities (Abrahamsen et al., 2008) but surprisingly
does not diminish the development of cancer-induced bone
pain (Figures 4G and 4H). No significant differences in the level
of bone degradation were observed (Figure 4I). Example X-rays
from a Nav1.7Wnt1 mouse (Figure 4J) and a littermate mouse
(Figure 4K) both show pronounced bone degradation (high-
lighted by the red arrows) in comparison to sham-operated
mice (Figure 4L). Furthermore, no overt fractures were
observed in either Nav1.7Wnt1 or littermate mice demonstratingtomized Nav1.7Advill (red squares, n = 8) and littermate (purple squares, n = 7)
n = 7).
k line/green square, n = 7) 14 days after SNT surgery, in comparison to vehicle
Data analyzed by two-way analysis of variance followed by the Bonferroni post
ividual points).
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Figure 5. Reversal of CCI-Mediated Mechanical Allodynia after
Tamoxifen-Induced Deletion of Nav1.7
Nav1.7ADERT2 (red squares, n = 8) mice develop mechanical allodynia normally
in comparison to littermate controls (white squares, n = 9) following CCI sur-
gery. However, activation of Advillin-CreERT2 through five daily intraperitoneal
tamoxifen injections (2 mg per day) reverses this mechanical allodynia in
Nav1.7ADERT2 mice but not Advillin-CreERT2 negative littermate controls. Data
analyzed by two-way analysis of variance followed by the Bonferroni post
hoc test. Results are presented as mean ± SEM. **p < 0.01 and ***p < 0.001
(individual points).that the observed behavior is related to cancer-induced bone
pain and not impaired mobility of the affected leg due to
bone fractures.
Deleting Nav1.7 in Adult Mice Reverses Neuropathic
Pain
Humans with recessive loss-of-function Nav1.7 mutations are
pain free (Cox et al., 2006, Goldberg et al., 2007), but specific
high-affinity antagonists of Nav1.7 have so far not produced dra-
matic analgesic effects (Schmalhofer et al., 2008). It is possible
that developmental deficits related to the loss of Nav1.7 in utero
could explain some aspects of Nav1.7-dependent pain. To
address this, an inducible DRG-specific Nav1.7 knockout mouse
strain (Nav1.7ADERT2) was generated using Advillin-CreERT2
(Lau et al., 2011). Lau et al. (2011) show that Advillin-CreERT2
has the same expression pattern as Advillin-Cre, following
tamoxifen induction. Figure 5 shows that uninduced
Nav1.7ADERT2 mice develop mechanical allodynia following CCI
surgery in the same manner as littermate controls. However,
mechanical allodynia is reversed in Nav1.7ADERT2 but not in
Advillin-CreERT2-negative, homozygous floxed (Scn9a) Nav1.7
littermate mice following tamoxifen treatment. These data pro-
vide further validation of Nav1.7 as a target for analgesic drug
development in adult humans.Figure 4. Oxaliplatin-Induced Pain and Cancer-Induced Bone Pain Do
Nav1.7Wnt1 (green squares, n = 7) and littermate (white squares, n = 13) mice tr
mechanical (A) and cold (B) allodynia. Nav1.8DTA (black squares, n = 10) and litterm
(i.v.) develop bothmechanical (C) and cold (D) allodynia. Limb use scores for the a
limb (F) of Nav1.7Wnt1 (green squares, n = 8) and littermate (white squares, n = 8)
hind limb (G) and percentage of body weight placed on the affected hind limb (H)
following cancer induction in the femur. Both Nav1.7Wnt1 (green column, n = 8) an
compared to sham operated mice (black column, n = 5) (I). Example of decreased
operatedmouse (L). Scale bars represent 2mm.Data analyzed by two-way analys
mean ± SEM. **p < 0.01 and ***p < 0.001 (individual points). See also Figure S3.
CDISCUSSION
Present views of the organization of the peripheral nervous sys-
tem have been formed by electrophysiological studies. Gasser
showed that fast conducting myelinated A-fibers were involved
in pain responses, together with slower conducting C-fibers
(Gasser, 1941). There has been a subsequent focus on C-fiber-
associated pain largely because the cells are easier to culture
and characterize electrophysiologically. The role of specialized
sensory neurons that only respond to damaging stimuli in pain
pathways was experimentally demonstrated by Burgess and
Perl (1967) and Bessou and Perl (1969) and the view that the in-
tensity of a stimulus could change innocuous sensing neurons
into damage-sensing neurons (intensity theory) was generally
abandoned. Electrophysiological studies suggested that there
were a range of different nociceptor subtypes, polymodal noci-
ceptors, cold, mechano-heat (CMH) fibers, and so on, based
on the electrical properties of teased fibers (often containing
more than one axon) that depolarize in response to various, often
superthreshold insults in anesthetized animals. These studies,
combined with the now discredited gate-control theory of pain
underpinned the view that pain was predominantly a C-fiber-
mediated event.
Recent behavioral genetic studies in unanesthetized awake
animals are incompatible with this analysis. For example, it is
clear that the neurons that respond to noxious thermal (heat) in-
sults are distinct from those involved in noxious mechanosensa-
tion when behavioral assays are employed (Abrahamsen et al.,
2008; Minett et al., 2012; Mishra et al., 2011). Cell ablation or
silencing strategies, where cell markers such as glutamate trans-
porters or sodium channels are used to define and delete/disrupt
subsets of sensory neurons, have shown that there is clear
specialization in terms of noxious input into the dorsal horn
(Abrahamsen et al., 2008; Lagerstro¨m et al., 2010, 2011; Minett
et al., 2012; Mishra et al., 2011). It is also clear that some A-fibers
are nociceptors and some C-fibers are low threshold mecha-
noreceptors or involved with definition of pleasurable stimuli
(Vrontou et al., 2013).
Previously, we reported that neuropathic pain develops nor-
mally in mice lacking Nav1.7 and Nav1.8 in the Nav1.8-positive
subset of sensory neurons (Nassar et al., 2005). However, the
present study provides evidence that some neuropathic pain
states depend upon sensory neuron input involving Nav1.7,
whereas other neuropathic pain states depend upon the activity
of Nav1.7 in both sensory and sympathetic neurons. Thus,
Nav1.7 is required for the development of pain in surgical models
of neuropathic pain. The sprouting of sympathetic neurons
into DRG of damaged nerves depends, surprisingly, upon theNot Require Nav1.7 Expression or Nav1.8+ Nociceptors
eated twice weekly (red arrows) with 3.5 mg/kg oxaliplatin (i.v.) develop both
ate mice (white squares, n = 11) treated twice weekly with 3.5mg/kg oxaliplatin
ffected hind limb (E) and percentage of body weight placed on the affected hind
mice following cancer induction in the femur. Limb use scores for the affected
of Nav1.8DTA (black squares, n = 9) and, littermate (white squares, n = 8) mice
d littermate (white column, n = 8) mice show similar decreases in bone density
bone density in a Nav1.7Wnt1 (J) and littermate (K) mouse, compared to a sham-
is of variance followed by the Bonferroni post hoc test. Results are presented as
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presence of Nav1.7 in these cells. The mechanism underlying
this phenomenon is unknown, but since the studies of Dogiel
and Ramo´n y Cajal in the 19th century, the existence of sympa-
thetic bundles surrounding sensory neurons in normal animals
has been described, with increased sprouting seen following
neuronal damage (McLachlan et al., 1993; Ramer and Bisby,
1998b). Sympathetic nerve block has been used effectively in
many pain states, and the application of beta blockers has
also proved effective in some situations (Lo´pez-A´lvarez et al.,
2012). Thus, norepinephrine acting on large diameter sensory
neurons seems to be able to lower pain thresholds and cause
ongoing pain (Roberts and Foglesong, 1988). Xie et al. showed
that repeated stimulation of sympathetic postganglionic neurons
within the dorsal ramus enhanced spontaneous activity in large
and medium diameter neurons and reduced thresholds of acti-
vation in large neurons following SNT surgery (Xie et al., 2010).
Interestingly, spontaneously active DRG neurons encapsulated
by sympathetic baskets always had conduction velocities above
9 m/s and were clearly distinct from the much slower unmyelin-
ated ‘‘classical’’ nociceptors (Xie et al., 2011). This spontaneous
activity could be reduced or eliminated by applying norepineph-
rine antagonists, or by precutting the gray ramus through which
sympathetic fibers innervate the DRG (Xie et al., 2010). We report
here that exogenous norepinephrine can cause pain in the
absence of Nav1.7, when sensory neurons are damaged (see
Figure 2G). A role for EPAC-1-mediated sensitization of Piezo2
mechanotransducing molecules has recently been shown to
be important for both touch and allodynia following SNT surgery
and is an example of the type of mechanism that may involve
peripheral sensitization through nonnociceptive sensory neu-
rons (Eijkelkamp et al., 2013).
Increasing evidence suggests that cancer-induced bone
pain is mechanistically different from other chronic pain states,
such as neuropathic and inflammatory pain. It has been shown
that the neurochemical changes observed in the spinal cord in
models of cancer-induced bone pain are different from those
observed in inflammatory and neuropathic pain states (Honore
et al., 2000). Whereas inflammatory models display increased
levels of substance P and calcitonin gene-related peptide in
the spinal cord, models of cancer-induced bone pain display
no changes in the levels of these neuropeptides (Honore et al.,
2000). However, increases in c-Fos expression and dynorphin-
expressing neurons have been reported in inflammatory, neuro-
pathic, and cancer-induced bone pain models (Abbadie and
Besson, 1992; Schwei et al., 1999;Wagner et al., 1993), suggest-
ing that central pain mechanisms may partially overlap. The
behavioral outcomes used to quantify cancer-induced bone
pain are substantially different from neuropathic and inflamma-
tory pain models consistent with the existence of distinct under-
lying mechanisms. Neuropathic and inflammatory pain states
have traditionally been measured using threshold responses
to evoked stimuli such as von Frey hairs, whereas alternative
outcome measures, such as limb use scoring and weight-
bearing ratios, have been developed for cancer-induced bone
pain models, as measures of evoked pain have been inconsis-
tent and unpredictable (Figures S4A and S4B).
In this study, we demonstrate that cancer-induced bone
pain and oxaliplatin-induced pain do not require the peripheral308 Cell Reports 6, 301–312, January 30, 2014 ª2014 The Authorsneuronal subpopulations that are essential for acute, inflamma-
tory, and neuropathic pain. Nav1.7 expression within the periph-
eral nervous system is necessary for acute, inflammatory, and
neuropathic pain behavior in mice (Minett et al., 2012; Nassar
et al., 2004), as well as in human CIP (Cox et al., 2006, Goldberg
et al., 2007) but not for either cancer-induced bone pain or oxa-
liplatin-induced pain. A role for inflammatory mediators such as
tumor necrosis factor-a, nerve growth factor, bradykinins, pros-
taglandins, and ATP has been identified in the development of
cancer-induced bone pain (Falk et al., 2012). Thus, tissue dam-
age and subsequent activation of the immune system associ-
ated with the progression of cancer-induced bone pain could
sensitize nociceptors to cause ongoing pain. However, the uni-
lateral sensitization of the affected limb demonstrates the impor-
tance of peripheral input in ongoing pain. A role for the atypical
sodium channel Nax implicated in sodium sensing has recently
been described, where lentiviral siRNA knockdown of this chan-
nel reverses pain-related behavior associated with tumor growth
(Ke et al., 2012). Nax is expressed in the medium to large diam-
eter sensory neurons that are also implicated in oxaliplatin-
evoked pain (Ke et al., 2012). Deleting Nav1.7, or ablating the
Nav1.8-positive nociceptor population, does not diminish the
pain-related behavior associated with either oxaliplatin or can-
cer-induced bone pain. However, the sodium channel blocker
mexiletine is protective against oxaliplatin-induced pain (Ega-
shira et al., 2010). This is consistent with the recent demonstra-
tion of an essential role for Nav1.6, in conjunction with delayed
rectifier potassium channels in oxaliplatin-evoked pain (Sittl
et al., 2012, Deuis et al., 2013). Nav1.6 expression is associated
with myelinated A-fibers rather than classical C-fiber-associated
nociceptors. Taken together, these observations are consistent
with pain resulting from input from neurons that normally sub-
serve innocuous sensation (Table 1).
Further evidence for the complexity of peripheral nociceptive
mechanisms comes from sodium channel gene ablation studies.
Global deletion of Nav1.3, Nav1.8, or Nav1.9 has quite different
effects on cold and mechanical allodynia produced by different
neuropathic pain models. These findings provide support for
the existence of multiple mechanisms involving different sub-
populations of sensory neurons that can produce apparently
identical pain phenotypes. Microarray technology has been
used to identify dysregulated transcripts common to different
pain states (Maratou et al., 2009). The logic of this approach is
that a single critical mechanism may underpin the pain caused
by a variety of stimuli and provide a potentially useful target of
new analgesic drug development. However, the evidence
accumulated here suggests that different peripheral cell types
and mechanisms lead to phenotypically similar pain states (see
Table 2). Mu¨ller (1842) first suggested that the quality of a sensa-
tion is defined by the central terminations of sensory nerves.
Recent advances in the use of genetically encoded calcium indi-
cators should allow us to examine whether redundant mecha-
nisms converge on similar pathways within the spinal cord and
midbrain (Zariwala et al., 2012).
These findings have significant implications for clinical prac-
tice. Recent attempts to phenotype neuropathic pain patients
as a prelude to rational drug treatment are a necessary first
step (Backonja et al., 2013), but the present results suggest
Table 1. Peripheral Sodium Channels and Pain Pathways
Pain Modality
Essential
Sodium
Channel
Peripheral Neuronal
Subpopulation
Classical nociceptive pain pathways
Acute (spinal) heat pain Nav1.7 Nav1.8-negative
sensory neurons
Acute mechanical pain Nav1.7 Nav1.8-positive
sensory neurons
Acute cold pain Nav1.8 Nav1.8-positive
sensory neurons
Inflammatory hyperalgesia Nav1.7 Nav1.8-positive
sensory neurons
Nonnociceptive pain pathways
Neuropathic mechanical allodynia Nav1.7 Nav1.8-negative
sensory neurons
Neuropathic cold allodynia Nav1.7 Nav1.8-positive
sensory neurons
Sympathetically maintained pain Nav1.7 Nav1.7-positive
sympathetic neurons
Atypical peripheral pain pathways
Oxaliplatin-evoked allodynia Nav1.6 A-fiber-associated
neurons
Cancer-induced bone pain Nax A-fiber-associated
neuronsthat this useful analysis will require further subdivision intomech-
anistically distinct pain sets. Given the absence of biomarkers,
and the uncertainty about mechanisms involved, the argument
for polypharmacy becomes appealing. Triple therapy has proved
revolutionary in HIV antiviral therapy (Bernardini and Maggiolo,
2013). There is no reason why multiple therapies should not be
routinely used in pain treatment. The often-remarked-upon fail-
ure of new analgesic drugs may be linked to a failure to distin-
guish mechanistically distinct pain syndromes, and an inability
to tease out useful effects of drugs on subsets of pain patients
in the overall noise of nonresponders.
In summary, we have provided evidence that some pain states
do not involve classical nociceptor activation, consistent with the
proposal of the intensity theory that suggests neurons respond-
ing to innocuous stimuli may activate central pain pathways in
some circumstances. The overwhelming evidence for redun-
dancy inpainmechanismscoupledwith a simplistic classification
of nociceptive mechanisms on the basis of early electrophysio-
logical studies helps to explain recent problems in developing
analgesic drugs. Further mechanistic studies and a combined
therapeutic attack on critical painmediators such as norepineph-
rine andproinflammatory cytokines aswell as the electrical appa-
ratus that underpins peripheral signaling to the CNS is a logical
route to pain treatment in the future.
EXPERIMENTAL PROCEDURES
Genotyping
Genomic DNAwas isolated from ear notches as described previously (Akopian
et al., 1999; Nassar et al., 2006; Abrahamsen et al., 2008; Minett et al., 2012;
Ostman et al., 2008).CBehavioral Testing
Animal experiments were approved by the UK Home Office and UCL ethics
committee. Touch perception thresholds were measured using the up-down
method for obtaining the 50% threshold using von Frey hairs (Chaplan et al.,
1994). Behavioral response to cooling (approximately 10C –15C) by acetone
test was performed (Bautista et al., 2006).
Spinal Nerve Transection at the Fifth Lumbar Segment
A modified version of the Kim and Chung model (Kim and Chung, 1992) of
peripheral neuropathy was adapted for use on mice (Minett et al., 2012).
Acetone and von Frey thresholds were recorded at baseline and up to
28 days after surgery.
Chronic Constriction Injury of the Sciatic Nerve
The Bennett and Xie model of peripheral neuropathy (Bennett and Xie, 1988)
was adapted for use onmice. Acetone and von Frey thresholds were recorded
at baseline and up to 28 days after surgery.
Oxaliplatin-Induced Pain
Oxaliplatin (Sigma) was administered intravenously by tail vein injection
(3.5 mg/kg). Mice received a total of four injections separated by 3 then
4 days (Renn et al., 2011).
Cancer-Induced Bone Pain
A model of metastatic bone pain was introduced by intrafemoral injection
of LL/2 lung carcinoma cells (Clohisy et al., 1996). Spontaneous and move-
ment-evoked pain response measures were used to evaluate pain behavior
up to 16 days after induction (Falk et al., 2013).
Induction of Advillin-CreERT2
Advillin-CreERT2 expression was induced via a series of five consecutive daily
2mg intraperitoneal (i.p.) injectionsof tamoxifen (Sigma-Aldrich) (Lauetal., 2011).
Chemical Sympathectomy
6-OHDA (Sigma) was dissolved in sterile saline containing 0.01% (w/v)
ascorbic acid (vehicle) and was injected intraperitoneally at a concentration
of 200 mg/kg (Leo et al., 1998). Control mice received an equivalent volume
of vehicle alone.
Immunocytochemistry
DRGs were excised from animals perfused with 4% paraformaldehyde. Serial
10 mm sections were collected. Slides were washed and blocked in 10% goat
serum in PBS +0.3% Triton for 1 hr at room temperature and incubated in the
primary antibody overnight at 4C. Primary antibodies were detected by incu-
bating with the secondary antibody at room temperature for 2 hr.
Quantification of Sympathetic Sprouting
Tissue samples were visualized and captured in monochrome and pseudo-
colored using HCImage 2.0.1.16. ImageJ64 analysis software (NIH) was
used to quantify sympathetic axons. To generate innervation density data,
the total area of DRG cell layer, excluding axonal tracts, was measured.
Following this, the length of TH-positive axons within the marked area was
measured. A reference image with known grid size was used to calculate units.
Quantification of Bone Degradation
Following dissection and fixation, radiographic images of the distal femur head
were obtained using a digital camera inside an enclosed cabinet during expo-
sure to an X-ray source (Faxitron MX-20). Each X-ray image was calibrated
to a standard aluminum wedge and the grayscale intensity quantified using
ImageJ. The calibrated grayscale value was used to quantify the relative
bone density of the distal femur for statistical analysis.
Statistics
Data were analyzed using the GraphPad Prism 5. Student’s t test (two-tailed)
was used for comparison of difference between two distributions. Multiple
groups were compared using one-way or two-way analysis of variance with
the Bonferroni post hoc test.ell Reports 6, 301–312, January 30, 2014 ª2014 The Authors 309
Table 2. Summary of Distinct Neuronal Subpopulations and Mechanisms Underlying Different Neuropathic Pain Models
VGSC Deleted from
Chronic Constriction Injury Spinal Nerve Transection Oxaliplatin-Induced Pain
Cold Allodynia Mechanical Allodynia Cold Allodynia Mechanical Allodynia Cold Allodynia Mechanical Allodynia
Nav1.3 CNS/PNS attenuated attenuated normal normal normal normal
Nav1.7 Nociceptors lost normal normal normal normal normal
Sensory neurons lost lost normal normal normal normal
Sympathetic and
sensory neurons
lost lost lost lost normal normal
Nav1.8 Nociceptors attenuated normal normal normal normal normal
Nav1.9 Nociceptors attenuated normal normal normal normal normal
VGSC, voltage-gated sodium channel; PNS, peripheral nervous system; CNS, central nervous system.SUPPLEMENTAL INFORMATION
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